ALTO-101
Small molecule
Evidence outlook · program status
On hold (2026-04-01), after a negative readout
After the Phase 2 CIAS proof-of-concept study missed its primary endpoints (topline 1 April 2026), Alto said it does not plan to advance ALTO-101 in CIAS independently, prioritises ALTO-207, and will explore partnering a modified-release oral formulation. The trials below are the program's evidence history; no evidence signal is assigned while development is paused.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06502964 NCT06502964 · Schizophrenia, Cognitive Impairment Registry: NCT06502964 | 2 | Theta band activity (Treatment Period 1 - Day 6 and Day 11; Treatment Period 2 - Day 6 and Day 11) 2026-02 | In progress: primary completion was expected 1 Feb 2026; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Competitive landscape
Other PDE4 drugs
apremilast, crisaborole, difamilast, Roflumilast (Daliresp), Roflumilast (Zoryve foam) and 5 more. Compare all 11 PDE4 drugs
This mechanism is crowded: 11 other tracked programmes target it, 8 of them ahead of this one.
This drug's own stage for Cognitive Impairment Associated with Schizophrenia: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| ALTO-101: this drug | Stage not on record | Small molecule | PDE4 | not yet graded | No reviewed efficacy summary in this indication | |
| Apremilast (Otezla) | Approved(overall) | Small molecule | PDE4 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Crisaborole (Eucrisa) | Approved(overall) | Small molecule | PDE4 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Difamilast (Moizerto / Adquey) | Approved(overall) | Small molecule | PDE4 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Roflumilast (Daliresp) | Approved(overall) | Small molecule | PDE4 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Roflumilast (Zoryve Foam) | Approved(overall) | Small molecule | PDE4 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Roflumilast (Zoryve) | Approved(overall) | Small molecule | PDE4 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Mufemilast | Phase 3(overall) | Small molecule | PDE4 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Prifemilast (HPP737) | Phase 3(overall) | Small molecule | PDE4 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Inidascamine (RL-007) | Phase 2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Morcamilast | Phase 2(overall) | Small molecule | PDE4 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| PALI-2108 | Phase 2(overall) | Small molecule | PDE4 | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Idrebormilast | Discontinued | Small molecule | PDE4 | Partial signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent